New Updates in Dyslipidemia Treatment
The most significant updates in dyslipidemia management include earlier and more aggressive LDL-C lowering with upfront combination therapy for extremely high-risk patients, expanded use of PCSK9 inhibitors and inclisiran, incorporation of bempedoic acid as an oral alternative, and routine lipoprotein(a) screening at least once in all adults. 1, 2
Key Treatment Paradigm Shifts
Risk Stratification Updates
The 2026 guidelines introduce the PREVENT-ASCVD risk calculator replacing older models, now calculating both 10-year and 30-year risk for adults aged 30-59 years 2. This represents a fundamental shift toward lifetime risk assessment rather than just short-term risk 3.
Risk enhancers now include:
- Lipoprotein(a) measurement (recommended at least once in all adults) 2
- Apolipoprotein B (ApoB) for selective cases 2
- Coronary artery calcium (CAC) scoring for borderline risk patients 3
Treatment Intensity by Risk Category
Extremely High-Risk Patients (Post-ACS, Recurrent Events):
- Initiate upfront combination therapy immediately rather than sequential add-on approach 1
- Target LDL-C <70 mg/dL, with <55 mg/dL preferred for extremely high-risk 1
- High-intensity statin + ezetimibe + PCSK9 inhibitor should be considered from the start 1
This represents a major departure from the traditional "start low, go slow" approach. The rationale: "lower is better for longer" and critically, "the earlier the better" 1.
Very High-Risk Patients (Established ASCVD, Diabetes, CKD):
- High-intensity statin as foundation 4
- Add ezetimibe if LDL-C remains elevated on maximal statin 4, 5
- Add PCSK9 inhibitor if still not at goal 4, 5
Expanded Pharmacologic Arsenal
Bempedoic Acid (New Oral Option):
- ATP-citrate lyase inhibitor providing additional 15-25% LDL-C reduction 4
- Critical advantage: Can be used in statin-intolerant patients 6
- Available as fixed-dose combination with ezetimibe 1
- Addresses the major gap for patients refusing or unable to tolerate statins
PCSK9 Inhibitors (Alirocumab, Evolocumab):
- Provide 45-58% additional LDL-C reduction when added to maximally tolerated statin 4
- FDA-approved for cardiovascular risk reduction, not just LDL-C lowering 4
- Dosing: Alirocumab 75-150 mg SC every 2 weeks; Evolocumab 140 mg every 2 weeks or 420 mg monthly 4
Inclisiran (Newest Addition):
- Small interfering RNA (siRNA) targeting PCSK9 7
- Major advantage: Twice-yearly dosing after initial loading (versus every 2-4 weeks for monoclonal antibodies)
- Addresses adherence issues with injectable therapies 6
Ezetimibe:
- Remains the first add-on therapy after statins 4, 5
- Proven cardiovascular outcomes benefit in IMPROVE-IT trial 4
- Well-tolerated, generic available 4
Treatment Goals Reintroduced
The 2026 guidelines reintroduce specific LDL-C, non-HDL-C, and ApoB treatment targets based on risk category 2. This reverses the 2018 approach that emphasized percent reduction rather than absolute targets.
Target hierarchy:
- Primary target: LDL-C
- Secondary target: Non-HDL-C (30 mg/dL higher than LDL-C target)
- Tertiary target: ApoB in select cases 2
Emerging Therapies in Late Development
Oral PCSK9 inhibitors are in late-stage development and may revolutionize treatment by combining the efficacy of injectable PCSK9 inhibitors with oral convenience 6.
Obicetrapib (CETP inhibitor) shows promise as safe and highly effective, unlike earlier failed CETP inhibitors 6, 7.
Critical Implementation Points
Common Pitfall: Waiting too long to intensify therapy. The evidence strongly supports early aggressive treatment, particularly post-ACS. Delaying combination therapy by months while titrating sequentially means months of inadequate risk reduction 1.
Cost and Access Issues: Despite proven efficacy, PCSK9 inhibitor uptake remains suboptimal due to cost and injection reluctance 6. Bempedoic acid and upcoming oral PCSK9 inhibitors may address these barriers.
Adherence Challenge: Long-term adherence remains problematic regardless of regimen 6. Twice-yearly inclisiran dosing may improve this, but the fundamental issue persists.
Practical Treatment Algorithm
All patients: Screen lipids, calculate PREVENT risk, measure Lp(a) at least once 2
Extremely high-risk (post-ACS, recurrent events): Start high-intensity statin + ezetimibe immediately; add PCSK9 inhibitor if LDL-C >70 mg/dL 1
Very high-risk (established ASCVD, diabetes, CKD): Start high-intensity statin; add ezetimibe if LDL-C >70 mg/dL; add PCSK9 inhibitor or bempedoic acid if still elevated 4, 5
Statin-intolerant patients: Use bempedoic acid ± ezetimibe as alternative 6
Injection-averse patients: Consider bempedoic acid or wait for oral PCSK9 inhibitors 6
The bottom line: With current therapeutic options, lipid disorders should be rendered rare. 1 The gap between guideline recommendations and real-world practice—where up to 70% of patients fail to meet goals—is no longer acceptable given available treatments.